Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Manni V et al. | 2004 | intact cell/cell culture, human oral keratinocytes | magnetic field, 50/60 Hz | 2 mT |
Berg H | 2003 | intact cell/cell culture, human myeloid leukemia cell line (K-562) and human non-Hodgkin lymphoma cell line (U-937) | magnetic field, 50/60 Hz, co-exposure | 8–55 mT |
Berg H et al. | 2003 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) and U937 cells (human leukemic monocyte cell line) and human lymphocytes | magnetic field, 50/60 Hz, co-exposure | 10–35 mT |
Tokalov SV et al. | 2003 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz, co-exposure | 60 µT |
Santini MT et al. | 2003 | intact cell/cell culture, human osteosarcoma cell lines (MG-63 and Saos-2) | magnetic field, 50/60 Hz | 500 µT |
Nascimento LF et al. | 2003 | bacterium, <i>Escherichia coli</i>/ATCC 25922 | magnetic field, 50/60 Hz | 500 µT |
Pang L et al. | 2002 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 4.4–13 mT |
Yoshizawa H et al. | 2002 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), K-562 (chronic myelogenous leukemia), MCF-7 (breast carcinoma), A-375 (malignant melanoma), H4 (glioma) | magnetic field, low frequency, 50/60 Hz | 2–500 µT |
Manni V et al. | 2002 | intact cell/cell culture, HaCaT cells (human keratinocytes cell line) | magnetic field, 50/60 Hz | 2 mT |
Tian F et al. | 2002 | intact cell/cell culture, CHO-K1 (Chinese hamster ovary K1) cells (Ku80-proficient) und xrs5 cells (Ku80-defizient; radiation sensitive mutant isolated from CHO-K1 cells) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.